iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences Meeting
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo
Press Release For Immediate Release NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION
March 15, 2021, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or
March 11, 2021, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF)